P5 - Poster Session 5
Event Time: | Thursday May 9, 2019 11:30 am to 6:30 pm |
Topic(s): | Practice, Policy, and Ethics, General Neurology, Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Headache, Movement Disorders, MS and CNS Inflammatory Disease, Neuro Trauma, Critical Care, and Sports Neurology, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-rehabilitation |
Director(s): | |
Description: | |
Completion Message: | |
CME Credits: | 0 |
Core Competencies: |
Start/End Time | Title | Faculty |
---|---|---|
Currently there are no events in the timeline. |
Speaker | Disclosure |
---|
Headache | |||
---|---|---|---|
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Undertreatment of Patients with Cluster Headache |
Disclosure: Dr. Mannava has nothing to disclose.
|
Behaviorial and Cognitive Neurology: Language, Memory, and Visuoperception II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Effect of Leukoaraiosis on Decline in Naming in Primary Progressive Aphasia |
Disclosure: Dr. Odolil has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Longitudinal Measures of Radiographic Outcomes as Predictors of Clinical Disability in Multiple Sclerosis: A 12-Year Study |
Disclosure: Dr. Feng has nothing to disclose.
|
Blood Pressure and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Out with the Old and In with the New - Understanding Barriers and Facilitators in Obtaining "New" Blood Pressure Goal for Patients with Ischemic Stroke |
Disclosure: Dr. Sico has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | A novel TTN deletion causes Autosomal Dominant Limb-Girdle Muscular Dystrophy with Dilated Cardiomyopathy |
Disclosure: Dr. Rich has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome in an Open-label Extension Trial (GWPCARE5) |
Disclosure: Dr. Patel has received research support from Greenwich Biosciences given to Nationwide Children's Hospital.
|
Neuro-rehabilitation: Stroke Recovery | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Swallowing outcomes and discharge destinations in acute-stroke tube-feeding-dependent dysphagia patients treated with neuromuscular-electrical-stimulation during inpatient rehabilitation |
Disclosure: Dr. Kushner has nothing to disclose.
|
Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Medial temporal lobe subfield volumes are spared in non-amnestic Alzheimer's disease |
Disclosure: Dr. Phillips has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Striatal Acetylcholine and Dopamine are Necessary for Motor Function in Parkinsonism |
Disclosure: Dr. Bamford has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 001 | Utility of whole body 18-FDG-PET in management of Tuberculous Meningitis: A preliminary study from a tertiary care institute of North India |
Disclosure: Dr. Modi has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Acute Headache Diagnosis in the Emergency Department: Accuracy and Safety of an Artificial Intelligence System |
Disclosure: Dr. Acosta has nothing to disclose.
|
Behaviorial and Cognitive Neurology: Language, Memory, and Visuoperception II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Anatomical Correlates of Verbal Fluency in Parkinson Disease |
Disclosure: Dr. Rodriguez-Porcel has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Dietary and Lifestyle Factors in Multiple Sclerosis Progression: Results from a 5-year Longitudinal MRI Study |
Disclosure: Dr. Hagemeier has nothing to disclose.
|
Blood Pressure and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Blood Pressure at Hospital Arrival Does Not Reliably Distinguish Hypertensive Intracerebral Hemorrhage |
Disclosure: Dr. Fakhri has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Relationships between DMD mutations and neurodevelopment in dystrophinopathy |
Disclosure: Dr. Thangarajh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Avexis.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Evaluation of Withdrawal Seizures During Conversion from Antiepileptic Drug Regimens Containing Carbamazepine to Eslicarbazepine Acetate Monotherapy |
Disclosure: Dr. Ramsay has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Sunovion Pharmaceuticals Inc., Eisai, and Allied Group of Companies. Dr. Ramsay has received research support from Marinus, Sage, Sunovion Pharmaceuticals Inc., Eisai, and Lundbeck.
|
Neuro-rehabilitation: Stroke Recovery | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Functional anomaly mapping using BOLD time-courses reveals local and distant dysfunction caused by stroke |
Disclosure: Dr. DeMarco has nothing to disclose.
|
Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Synergistic neuropathology resulting from co-expression of TDP-43 and tau protein in vivo |
Disclosure: Dr. Moszczynski has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | L-Dopa-Induced Dyskinesias are Reduced by Propranolol in Parkinsonian Mice |
Disclosure: Dr. Bamford has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 002 | Prophylactic Palmitoylethanolamide Prolongs Survival and Decreases detrimental Inflammation in Aged Mice with Bacterial Meningitis |
Disclosure: Dr. Heide has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Use of Traditional Medicine for Primary Headache Disorders in Kuwait. |
Disclosure: Dr. Alshawaf has nothing to disclose.
|
Behaviorial and Cognitive Neurology: Language, Memory, and Visuoperception II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Network-Based Approach to the Role of the Inferior Frontal Gyrus in Word Retrieval and Selection |
Disclosure: Dr. Mass has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Vitamin D and Tobacco Use and Long-Term Clinical and MRI Outcomes among CIS patients: 11-year Follow-up of BENEFIT. |
Disclosure: Dr. Martinez-Lapiscina has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CIHR, Research Manitoba, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, Crohn’s and Colitis Canada, National Multiple Sclerosis Society, CMSC.
|
Blood Pressure and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Low and steady: Evidence for target blood pressure 24 hrs post-thrombectomy |
Disclosure: Dr. Elangovan has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | NEO1 and NEO-EXT Studies: Long-Term Safety of Repeat Avalglucosidase Alfa Dosing for 4.5 Years in Patients With Late-Onset Pompe Disease |
Disclosure: Dr. Dimachkie has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alnylam, Audentes, CSL-Behring, Sanofi Genzyme, Momenta, NuFactor, RMS Medical, Shire Takeda and Terumo. Dr. Dimachkie has received research support from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, CSL-Behring, FDA/OPD, GlaxoSmithKline, Genentech, Grifols, MDA, NIH, Novartis, Genzyme, Octapharma, Orphazyme, UCB Biopharma, Viromed and TMA.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Adherence to AED treatment for patients with focal seizure receiving monotherapy with eslicarbazepine acetate or prior generation generics: Evidence from a large US commercial claims database |
Disclosure: Dr. Mehta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion Pharmaceuticals Inc.
|
Neuro-rehabilitation: Stroke Recovery | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Causes of interruption of acute rehabilitation and readmission after stroke |
Disclosure: Dr. Herrmann has nothing to disclose.
|
Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Predicting Clinical Course in Persons with Mild Cognitive Impairment using structural MRI. |
Disclosure: Dr. Ezzati has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Glial alpha-synuclein induces a unique transcriptional program in vivo |
Disclosure: Dr. Olsen has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 003 | Nontraumatic Spontaneous Pneumocephalus in Clostridium Septicum Central Nervous System Infection – A Case Report |
Disclosure: Dr. Karukote has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Filling the Gap: CSF Fistula as a Presentation of Intracranial Hypertension |
Disclosure: Dr. Szewka has nothing to disclose.
|
Behaviorial and Cognitive Neurology: Language, Memory, and Visuoperception II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | The Contribution of Residual Anatomical Brain Networks in Language Recovery in Post-Stroke Aphasia |
Disclosure: Dr. Kelkar has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Adjusting neurofilament light levels using an MRI-based estimate of total axonal bulk improves its prediction of MS progression |
Disclosure: Dr. Phillips has nothing to disclose.
|
Blood Pressure and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Sympathetic Nervous System Dysfunction Correlates with Increased Blood Pressure Variability after Acute Stroke |
Disclosure: Dr. De Havenon has received research support from AMAG Pharmaceuticals and Regeneron Pharmaceuticals.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | GNE Myopathy Biomarkers: Essential for Diagnosis and Response to Therapy |
Disclosure: Dr. Malicdan has received royalty, license fees, or contractual rights payments from Leadiant Biosciences. Dr. Malicdan has received research support from Leadiant Biosciences.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Adjunctive Perampanel in Pediatric Patients with Epilepsy: Population Pharmacokinetic (PK) and Exposure-Response Analyses |
Disclosure: Dr. Majid has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai Ltd.
|
Neuro-rehabilitation: Stroke Recovery | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | The Relationship of Neurologic Impairments to Post-Stroke Fatigue in an Urban, Minority Population |
Disclosure: Dr. Yee has nothing to disclose.
|
Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Preliminary neuropathological findings in porcine brains following hypobaric exposure |
Disclosure: Dr. Cook has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Over Expression of PERK Suppresses the Neurodegenerative Phenotypes in PINK1 Mutant Flies by Enhancing Mitochondrial Function |
Disclosure: Dr. Cui has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 004 | Acute Disseminated Streptococcus Anginosus Abscesses in a Young Immunocompetent Patient |
Disclosure: Dr. Khalife has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | An Interdisciplinary Approach Between Neurology and Neurosurgery for the Treatment of Headaches in the Setting of Aqueductal Stenosis |
Disclosure: Dr. Baker has nothing to disclose.
|
Behaviorial and Cognitive Neurology: Language, Memory, and Visuoperception II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Impaired Global Network Topology in Residual Connectomes in Stroke-induced Aphasia |
Disclosure: Dr. Medaglia has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | A History of Migraine Headache is Associated with Worse Disability and Walking Speed in a Cohort of Patients with MS |
Disclosure: Dr. Damian has nothing to disclose.
|
Blood Pressure and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | High In-Hospital Systolic Blood Pressure Variability and Poor Functional Outcomes in Primary Intracerebral Hemorrhage Patients |
Disclosure: Dr. Alex has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | The IPANEMA Study: Top Line Results from an Investigator-Initiated Multi-site Late-onset Pompe Disease Prevalence Study |
Disclosure: Dr. Wencel has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome in an Open-Label Extension Trial |
Disclosure: Dr. Halford has received personal compensation for consulting from GW Pharma and NCGS. Dr. Halford has received research support from Takeda, GW Pharma, SK Life Sciences, The Epilepsy Study Consortium, Brain Sentinel, and Philips.
|
Neuro-rehabilitation: Stroke Recovery | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Repetitive Transcranial Magnetic Stimulation in Improving Lower Extremity Function and Gait Among Stroke Patients: A Meta-analysis |
Disclosure: Dr. Matic has nothing to disclose.
|
Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Connectomics in Brain Aging and Dementia |
Disclosure: Dr. Chang has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | A kinome-wide Drosophila RNAi screen identifies glial adenylate kinases as modifiers of neuronal alpha-synuclein toxicity |
Disclosure: Dr. Olsen has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 005 | Listeria meningoencephalitis in an immunocompetent child |
Disclosure: Dr. Kaul has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Severity of Post-traumatic Headache in relation to Severity of TBI, PTSD and severe depression in Veterans of recent wars |
Disclosure: Dr. Couch has received personal compensation in an editorial capacity for Springer.
|
Frontotemporal Dementia II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Greater Relative White Matter Burden is a Distinct Feature of Tauopathies in Frontotemporal Degeneration Spectrum |
Disclosure: Dr. Giannini has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Serum Neurofilament Light Chain and Glial Fibrillary Acid Protein in Patients With Multiple Sclerosis |
Disclosure: Dr. Ayrignac has nothing to disclose.
|
Blood Pressure and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Blood Pressure Variability Post Mechanical Thrombectomy And Outcomes |
Disclosure: Dr. Vu has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | A Novel Homozygous TNNT1 Missense Mutation in a French-Canadian Kindred Causing a Unique Clinical and Pathological Phenotype of Congenital Nemaline Myopathy with Rods, Cores and Lobulated Fibers |
Disclosure: Dr. Pellerin has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Efficacy and Tolerability of Adjunctive Brivaracetam in Adults With Focal Seizures by Antiepileptic Drug Treatment History: Post Hoc Analysis |
Disclosure: Dr. Klein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Yes. Abbott: consultant; Alliance: medical advisory board; Acquestive: ad board; Eisai: consultant speaker; Lundbeck: research support; Sunovion: speaker; UCB Pharma: consultant, speaker.. Dr. Klein has received research support from Yes. Lundbeck.
|
Neuro-rehabilitation: Stroke Recovery | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | A Pilot Study of Right Cerebellar tDCS as a Therapeutic Adjuvant in Chronic Aphasia after Left-Hemisphere Stroke |
Disclosure: Dr. Dvorak has nothing to disclose.
|
Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | A Care Pathway for Post-Stroke Spatial Neglect: Initial Analysis of a Practice-Based Rehabilitation Research Network |
Disclosure: Dr. Barrett has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with emedicine/WebMD. Dr. Barrett has received research support from Dart Neuroscience and Brightcloud International funded research projects she led through the Kessler Foundation.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | PBT434 Prevents a-synuclein Aggregation, Neuron Loss, Motor Dysfunction and Reduces Glial Cell Inclusions in a Transgenic Mouse Model of Multiple System Atrophy |
Disclosure: Dr. Finkelstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prana Biotechnology. Dr. Finkelstein has received research support from Prana Biotechnology.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 006 | Late-Onset Austrian Syndrome in a Patient with Bacterial Meningitis |
Disclosure: Dr. Shapouran has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | One and Done: A Case Series of Large Volume Occipital Nerve Blocks for the Treatment of Occipital Neuralgia |
Disclosure: Dr. Mathew has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Avanir, Teva, Biomobie staff, Amgen, Allergan, Promius, and Takeda.. Dr. Mathew has received personal compensation in an editorial capacity for Practical Neurology. Dr. Mathew has received research support from Biomobie.
|
Frontotemporal Dementia II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Plasma neurofilament light chain predicts disease progression in asymptomatic genetic frontotemporal dementia |
Disclosure: Dr. Rojas -Martinez has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | The association between serum neurofilament light chain, atrophied lesion volume and brain atrophy with disability progression in multiple sclerosis |
Disclosure: Dr. Tavazzi has nothing to disclose.
|
Blood Pressure and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Patients with Parenchymal Hemorrhagic Transformation and Poor Functional Outcome Have Distinct Systolic Blood Pressure Trajectories 72 hours After Mechanical Thrombectomy |
Disclosure: Dr. Kodali has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | GNE Myopathy in Turkey: Clinical Features and Novel Mutations |
Disclosure: Dr. Durmus has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | The proposed multimodal mechanism of action of cannabidiol (CBD) in epilepsy: modulation of intracellular calcium and adenosine-mediated signaling |
Disclosure: Dr. Nichol has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as an employee of Greenwich Biosciences Inc..
|
Neuro-rehabilitation: Stroke Recovery | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Effect of Training Eye Hand Coordination Using Emerging Natural User Interface Technologies for Improving Hand Function in Stroke Survivors- A Randomized Controlled Study |
Disclosure: Dr. Choudhary has nothing to disclose.
|
Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Machine Learning of Quantified Volumetric MR Imaging for Diagnostic Delineation of Alzheimer’s Dementia and Mild Cognitive Impairment in the Alzheimer's Disease Neuroimaging Initiative |
Disclosure: Dr. Raji has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Brain reader.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Dopaminergic Grafts Prevent Risk Of Secondary Parkinsonism In Cocaine Self-administering Rats |
Disclosure: Dr. Venkiteswaran has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 007 | Read Between the Lyme's: Case Series of Bannwarth Syndrome |
Disclosure: Dr. Vu has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Syndrome of Transient Headache and Neurological Deficits with Cerebrospinal Fluid Lymphocytosis (HaNDL): A Case Report with Newly Described Electroencephalography (EEG) findings, Symptomatic Treatment Strategies, and Literature Review |
Disclosure: Dr. Hooshmand has nothing to disclose.
|
Frontotemporal Dementia II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Progress and Participant Characterization in the Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL) Rare Disease Clinical Research Consortium |
Disclosure: Dr. Boxer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie, Asceneuron, Cellgene, Ipierian, Ionis, Janssen, Merck, Novartis, Toyama and UCB. Dr. Boxer holds stock and/or stock options in Alector and Aeton Therapeutics. Dr. Boxer has received research support from NIH, the Tau Consortium, the University of California Cures Alzheimer’s Disease program, the Bluefield Project to Cure FTD, Corticobasal Degeneration Solutions, and the following companies: Avid, Biogen, Bristol Myers Squibb, C2N Diagnostics, Cortice Biosciences, Eli Lilly, Forum Pharmaceuticals, Genentech, Roche and TauRx.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | HLA genotype as a marker of Multiple Sclerosis prognosis: results from a multicentric extension study |
Disclosure: Dr. Lysandropoulos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma.
|
Blood Pressure and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Examining the Mortality Benefit of Various Post Ischemic Stroke/TIA Hypertension Goals – an VA-based Observational Study |
Disclosure: Dr. Sico has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Long-Term Efficacy of Dichlorphenamide for the Treatment of Primary Periodic Paralysis (PPP) |
Disclosure: Dr. Johnson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron, Strongbridge, Vertex, Fulcrum, and AveXis. Dr. Johnson has received personal compensation in an editorial capacity for Continuum. Dr. Johnson has received royalty, license fees, or contractual rights payments from University of Rochester. Dr. Johnson has received research support from Acceleron, CSL Behring, Fulcrum, Vertex, and AveXis.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Perampanel in Real-World Clinical Care of Patients with Epilepsy: Retrospective Phase IV Study 506 – Second Interim Analysis |
Disclosure: Dr. Wechsler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with for Alexza, Eisai, GW Pharmaceuticals, Lundbeck, Sunovion, Cyberonics, UCB Pharma, UCB Pharma, and Upsher-Smith.Dr. Wechsler has received research support from Alexza, Eisai, GW Pharmaceuticals, Lundbeck, Marinus, Pfizer, SK Life Science, Sunovion, UCB Pharma, and Upsher-Smith.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Action Observation Training Increases Dynamic Functional Connectivity in Patients with Multiple Sclerosis |
Disclosure: Dr. Cordani has nothing to disclose.
|
Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Creutzfeldt-Jakob Disease (CJD) Presenting as Epilepsia Partialis Continua: An Uncommon Presentation |
Disclosure: Dr. Milani has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Study of Yerba Mate (Ilex Paraguariensis) as a Neuroprotective Agent of Dopaminergic Neurons in an Animal Model of Parkinson's Disease |
Disclosure: Dr. Tribbia has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 008 | Microvessel Cerebral Vasculitis and Peripheral Neuropathy as Neurologic Manifestations in Rocky Mountain Spotted Fever |
Disclosure: Dr. Danielson has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Quality of life in patients with cluster headache during the active periods |
Disclosure: Dr. Kim has nothing to disclose.
|
Frontotemporal Dementia II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Characteristics and Progress on 369 Subjects in the Longitudinal Evaluation Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol |
Disclosure: Dr. Forsberg has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | No Association Between Lymphocyte Pharmacodynamics and Disability Following Alemtuzumab Treatment in Patients With Relapsing-Remitting Multiple Sclerosis |
Disclosure: Dr. Meuth has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Almirall, Amicus Therapeutics Germany, Bayer, Biogen, Celgene, Chugai Pharma, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, QuintilesIMS, Roche, Sanofi-Aventis, and Teva. Dr. Meuth has received research support from Almirall, Amicus Therapeutics Germany, Bayer, Biogen, Celgene, Chugai Pharma, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, QuintilesIMS, Roche, Sanofi-Aventis, and Teva.
|
Blood Pressure and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Admission Blood Pressure and Outcome after Successful Recanalization: a collaborative pooled analysis |
Disclosure: Dr. Anadani has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | A Survey of Patient-Identified Symptom Themes and Attitudes Toward Clinical Trials in Facioscapulohumeral Muscular Dystrophy (FSHD) |
Disclosure: Dr. Shirilla has received research support from Acceleron Pharma.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Study 506 – Second Interim Analysis of a Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Pediatric Subgroup (Aged <12 Years) |
Disclosure: Dr. Moretz has nothing to disclose.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Remotely Supervised Transcranial Direct Current Stimulation (RS-tDCS) Paired with a Hand Exercise Program to Improve Manual Dexterity in Progressive Multiple Sclerosis: A Randomized Sham Controlled Trial |
Disclosure: Dr. Feinberg has nothing to disclose.
|
Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Young-onset Creutzfeldt-Jakob disease with neuropsychiatric presentation and prolonged disease course |
Disclosure: Dr. Dhanapalaratnam has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Exploring the role of the basal ganglia in the control and learning of motor sequences in mice |
Disclosure: Dr. Riccelli has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 009 | Eisenmenger Syndrome presenting as Focal Seizures |
Disclosure: Dr. English has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | A Tale of two headaches – Use of Dynamic CT Myelogram to Localize Cerebrospinal Fluid Leak |
Disclosure: Dr. Schachter has nothing to disclose.
|
Cerebral Venous Sinus Thrombosis (CVST) | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Cerebral venous thrombosis from thrombocytosis in a patient with thalassemia and splenectomy |
Disclosure: Dr. Osman has nothing to disclose.
|
Frontotemporal Dementia II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | The Multidomain Impairment Rating (MIR) Scale: Initial Reliability Data on a Multidimensional Scale for FTLD |
Disclosure: Dr. Boeve has received research support from Biogen and Alector.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Predicting EDSS in MS through Imaging Biomarkers Using Artificial Neural Networks |
Disclosure: Dr. Chaar has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | A novel frameshift mutation in DNA2 causes early onset myopathy with velopharyngeal weakness and cardiac arrhythmias |
Disclosure: Dr. Gonzalez Del Angel has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Comparative Neuropsychological Effects of Carbamazepine and Eslicarbazepine Acetate |
Disclosure: Dr. Meador has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Epilepsy Study Consortium for Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, UCB Pharma and Vivus Pharmaceuticals. Dr. Meador has received research support from Sunovion.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Clinical and fMRI Effects of Action Observation and Motor Imagery Training on Dual-Task Performances in Parkinson’s Disease Patients With Postural Instability and Gait Disorders |
Disclosure: Dr. Sarasso has nothing to disclose.
|
Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | A case of Lymphomatosis Cerebri: a diagnostic challenge |
Disclosure: Dr. Sheng has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | Progression of Parkinson’s Disease: A Longitudinal MRI Study of Functional Brain Connectome in a Large Cohort of Patients |
Disclosure: Dr. Filippi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Merk-Serono, Novartis, Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, Roche.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 010 | A Rare Case of Mucormycosis Clivus Osteomyelitis Presenting With Stroke-Like Symptoms |
Disclosure: Dr. Jacobson has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Features of episodic cluster headache in the real world setting: clinical characteristics from a large, multi-national, cross-sectional survey |
Disclosure: I am full-time employee and a stock shareholder of Eli Lilly and Company.
|
Cerebral Venous Sinus Thrombosis (CVST) | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Cerebral Venous Thrombosis In A Single Center Tertiary Hospital Of A South East Asian Country (CVSTS Study) – A Retrospective Study On The Clinical Profiles Of Patients with Cerebral Venous Thrombosis |
Disclosure: Dr. Senga has nothing to disclose.
|
Neuroimaging: Aging, Vascular and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Brain glucose metabolism in Lewy Body Dementia: implications for diagnostic criteria |
Disclosure: Dr. CAMINITI has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Loss of Brain Iron is Linked to Disability in Multiple Sclerosis - The Difference Between Concentration and Mass of Iron |
Disclosure: Dr. Hagemeier has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Carotid Artery Dissection in a Young Woman with Ullrich Congenital Muscular Dystrophy |
Disclosure: Dr. Said-Said has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Time Course of Efficacy and Tolerability Outcomes With Adjunctive Brivaracetam in Adults: A Post Hoc Analysis |
Disclosure: Dr. Meador has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Epilepsy Study Consortium for Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, UCB Pharma and Vivus Pharmaceuticals. Dr. Meador has received research support from Sunovion.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Interventional First-Person Video Game Training Reduces Fall Risk in Parkinson’s Disease by Improving Gait, Contrast Sensitivity, Visual Acuity and Cognition |
Disclosure: Dr. Koul has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Different Patterns of Brain Activity During Lower Limb Movements in Parkinson’s Disease Patients With and Without Freezing of Gait |
Disclosure: Dr. Piramide has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 011 | Cryptococcus Strikes Again: Recurrent Cryptococcal Meningitis in an Immunocompetent Host |
Disclosure: Dr. McDermott has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Trend of Cluster Headache Hospitalizations and their Associated Outcomes, a National Four Year Retrospective Review. |
Disclosure: Dr. Chung has nothing to disclose.
|
Cerebral Venous Sinus Thrombosis (CVST) | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Novel Oral Anticoagulants (NOACs) vs. Warfarin in the Treatment of Cerebral Venous Sinus Thrombosis (CVST): A retrospective study of functional and radiographic outcomes among patients enrolled in BEAST (Biorepository to Establish the Aetiology of Sinovenous Thrombosis) at UVA. |
Disclosure: Dr. Wells has nothing to disclose.
|
Neuroimaging: Aging, Vascular and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | 18F-AV-1451 Tau Tracer Uptake Correlates with Medial Temporal Lobe Subregional Atrophy in Amyloid Negative Individuals |
Disclosure: Dr. Das has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Rancho Biosciences.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Unilateral Motor Progression in Multiple Sclerosis: Association with a Single Critical Corticospinal Tract Lesion |
Disclosure: Dr. Sechi has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | The Potential Role of Estrogen in Moderating Symptom Severity in Women with RYR1-Related Myopathy |
Disclosure: Dr. Sharp has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Long-term Retention on Adjunctive Brivaracetam in Adults With Focal Seizures Previously Exposed to Carbamazepine, Lamotrigine, Levetiracetam, or Topiramate: A Post Hoc Analysis |
Disclosure: Dr. Chung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ucb, Sunovion, Lundbeck, Eisai. Dr. Chung has received research support from Ucb, SK Life Sciences.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Motor Function of Individuals with HNRNPH2-related Disorders. |
Disclosure: Dr. Salazar has received research support fromSMA Foundation, Biogen, Roche, AveXis, Mallinckrodt, Ultragenyx, PTC Therapeutics, Sarepta Therapeutics, and the Jain Foundation. .
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Functional Network Connectivity Predicts Spreading of Cortical Atrophy in Parkinson’s Disease |
Disclosure: Dr. Agosta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 012 | Comparison of Lumbar and Ventricular Cerebrospinal Fluid for Diagnosis and Monitoring of Meningitis |
Disclosure: Dr. Kakadia has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Intravenous Fosphenytoin as Rescue Treatment in Trigeminal Neuralgia Crisis |
Disclosure: Dr. Schnell has nothing to disclose.
|
Cerebral Venous Sinus Thrombosis (CVST) | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Study of the factors predicting clinical outcome in patients with Cerebral Venous Sinus Thrombosis |
Disclosure: Dr. Suhana has nothing to disclose.
|
Neuroimaging: Aging, Vascular and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Abnormal neuropsychological memory testing and hippocampal volume in a clinical population. |
Disclosure: Dr. Ruchinskas has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis |
Disclosure: Dr. Hemond has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | TTR Knockdown Therapy in Patients with hATTR Amyloidosis Who Have Disease Progression despite Liver Transplant |
Disclosure: Dr. Moshe-Lilie has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Experience with Eslicarbazepine Acetate Treatment at a Pediatric Epilepsy Center |
Disclosure: Dr. Tanritanir has nothing to disclose.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | A Mixed-Methods Evaluation of Neurorehabilitation Resources for Pediatric Cerebral Malaria Survivors in Blantyre, Malawi |
Disclosure: Dr. Boubour has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Dual-Task in Parkinson’s Disease: A Gait Analysis and Functional MRI Study |
Disclosure: Dr. Sarasso has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 013 | Acute Chorea associated with Group C Streptococcus Pharyngitis |
Disclosure: Dr. Zaribaf has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Assessment and Management of Patients with Headache Referred to a General Neurology Consultation Service |
Disclosure: Dr. Fearon has nothing to disclose.
|
Cerebral Venous Sinus Thrombosis (CVST) | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Cerebral Venous Thrombosis and Intracerebral Hemorrhage due to Pegaspargase Therapy for Acute Lymphoblastic Leukemia |
Disclosure: Dr. Scarsella has nothing to disclose.
|
Neuroimaging: Aging, Vascular and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Cholinergic-Related White Matter Lesion Load is Associated with Alzheimer’s Disease-Signature Cortical Thickness: The Northern Manhattan Study |
Disclosure: Dr. Caunca has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Oligoclonal band number as a predictor of multiple sclerosis disease course |
Disclosure: Dr. Perrone has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Lack of Genotype-Phenotype Correlation in Individuals with DMPK Expansions |
Disclosure: Dr. Lindy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GeneDx.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Inpatient Hospitalization Risk in Medicaid Patients with Epilepsy Before and After Perampanel Treatment |
Disclosure: Dr. Chatterjee has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai inc..
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Restoration of Barnes maze, Protein Kinase M? and MAP2 by Minocycline plus N-Acetylcysteine when first dosed 72 hours after experimental traumatic brain injury |
Disclosure: Dr. Rahman has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | Microstructure alterations in the midbrain of Parkinson’s patients: a multishell diffusion MRI study |
Disclosure: Dr. Chen has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 014 | A Case of Neurobrucellosis in a non-endemic area |
Disclosure: Dr. Bronstein has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Acute and preventive treatment patterns in episodic cluster headache: findings from the United States, United Kingdom and Germany |
Disclosure: Dr. Nichols has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Nichols holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Nichols was involved as an investigator. Dr. Nichols holds stock and/or stock options in Eli Lilly and Company.
|
Cerebral Venous Sinus Thrombosis (CVST) | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Reactive thrombocytosis related cerebral venous thrombosis: A rare complication of untreated iron deficiency anemia |
Disclosure: Dr. Vaddiparti has nothing to disclose.
|
Neuroimaging: Aging, Vascular and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Periventricular Cerebral Blood Flow as a Biomarker for Cerebral Small Vessel Disease |
Disclosure: Dr. Dolui has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Cognition as a Disability Progression Marker: Two-Years Follow-Up of People with Multiple Sclerosis |
Disclosure: Dr. Motyl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanogi Genzyme, Novartis.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | mRna Expression Genes Associated To Myofibrillar Myopathies – Preliminary Study |
Disclosure: Dr. Carvalho has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Efficacy and Tolerability of Switching from Traditional Sodium Channel Blockers to Lacosamide in Epilepsy Patients |
Disclosure: Dr. Kim has nothing to disclose.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | The cofilin/Limk1 pathway controls the rate of regenerating motor axons |
Disclosure: Dr. Da Silva has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Impaired midbrain networks connectivity underlies freezing of gait in Parkinson’s disease |
Disclosure: Dr. Droby has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 015 | Immunomodulating Biologics and sCJD |
Disclosure: Dr. Lee has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Idiopathic Orbital Inflammation Presenting as Hemicrania Continua |
Disclosure: Dr. Duvall has nothing to disclose.
|
Cerebral Venous Sinus Thrombosis (CVST) | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Clinical course of seizures in patients with cerebral venous thrombosis |
Disclosure: Dr. Uygun has nothing to disclose.
|
Neuroimaging: Aging, Vascular and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Associations Between Amyloid Burden, White Matter Hyperintensities and Cognition in Cognitively Normal Older Adults |
Disclosure: Dr. Chapin has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Baló Concentric Sclerosis: Benign Evolution in a Tunisian Population |
Disclosure: Dr. Landolsi has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Transition to Adulthood in Duchenne/Becker Muscular Dystrophy |
Disclosure: Dr. Donaldson has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Analysis of Patient Characteristics and Outcomes by Prior AED use: Data from Pooled Observational Studies of Routine Perampanel use across Europe |
Disclosure: Dr. Trinka has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Eisai, Novartis, Gerrot-Lannach, BIAL, Takeda, Biogen, Newbridge, Sunovion. Dr. Trinka has received research support from Eisai Europe Ltd, GSK, Biogen-Idec, Novartis, Red Bull, Bayer, and UCB.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Activity monitoring in neuromuscular disease: Successes, challenges, and a path forward |
Disclosure: Dr. Lowes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Inc., Bristol Meyers-Squibb, Pfizer, and Sarepta Therapeutics. Dr. Lowes has received research support from Novartis and Sarepta Therapeutics.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Tracking Cortical Changes Throughout Cognitive Decline in Parkinson’s Disease: A Longitudinal MRI Study |
Disclosure: Dr. Canu has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 016 | Lyme Neuroborreliosis Initially Presenting as a Cavernous Sinus Syndrome: A Case Report |
Disclosure: Dr. Rinehardt has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Predictors of 30-Day Readmission Post Index Hospitalization for Cluster Headache: 5 Years National Estimate |
Disclosure: Dr. Kim has nothing to disclose.
|
Cerebral Venous Sinus Thrombosis (CVST) | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Safety and Effectiveness of Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) in Patients with Concurrent Migraine Headaches and Focal Neurological Deficits. |
Disclosure: Dr. Singh has nothing to disclose.
|
Neuroimaging: Aging, Vascular and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Assessment of Deep Medullary Veins on 3T MRI in a Population-based Cohort |
Disclosure: Dr. Ao has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Serum GFAP Associates with Neurofilament Light and Disease Severity in Late Multiple Sclerosis |
Disclosure: Dr. Airas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche, Merck . Dr. Airas has received research support from Sanofi-Genzyme.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | A Novel Case of Overlapping of Myotonic Dystrophy Type 2 and Bethlem Congenital Muscular Dystrophy |
Disclosure: Dr. Chalia has nothing to disclose.
|
Epilepsy: Antiseizure Medications III | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Study 506 – Second Interim Analysis of a Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Adolescent Subgroup (Aged 12 to <18 Years) |
Disclosure: Dr. Segal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Lundbeck, Nurticia, Novartis, Greenwich, Epitel, Encoded Therapeutics and Qbiomed.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | New treatments, now what: A pilot study investigating the use of in-home body-weight support harness systems to maximize the therapeutic benefit of novel treatments for spinal muscular atrophy. |
Disclosure: Dr. Iammarino has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Relationships Between Substantia Nigra Resting State Functional Connectivity and Uric Acid in REM Sleep Behavior Disorder and Parkinson’s Disease |
Disclosure: Dr. Ellmore has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 017 | Bartonella Papillitis Mimicking Anti-MOG Optic Neuritis |
Disclosure: Dr. Sguigna has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Accuracy of Pre-Headache Clinic SUNCT Diagnosis: A Cautionary Tale |
Disclosure: Dr. Wax has nothing to disclose.
|
Neuroimaging: Aging, Vascular and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Optical Properties and Oximetry Parameters of Cerebral Atrophic and Normal Regions in Healthy Volunteers |
Disclosure: Dr. Roveri has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Characterization of the Immunophenotype of Clinically Isolated Syndrome Patients Who Convert or Not To Multiple Sclerosis |
Disclosure: Dr. Lee has nothing to disclose.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Congestive Heart Failure is Strongly Associated with Hereditary Hemorrhagic Telangiectasia (HHT): Analysis of a Large National Database |
Disclosure: Dr. Farooqui has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | X-Linked Myotubular Myopathy and Fragile X Syndrome in a Female Patient |
Disclosure: Dr. Paul has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Aura as a Predictor of Outcome after Epilepsy Surgery |
Disclosure: Dr. Grossman has nothing to disclose.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | AbobotulinumtoxinA, onabotulinumtoxinA and incobotulinumtoxinA neurotoxin content and activity: Potential implications for duration of efficacy in patients |
Disclosure: Dr. Field has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Longitudinal Evolution of White Matter Damage in Parkinson’s Disease |
Disclosure: Dr. Scamarcia has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 018 | Diagnostic Challenge: Sporadic Creutzfeldt-Jakob Disease (sCJD) Presenting with Isolated Visual Symptoms |
Disclosure: Dr. Morawo has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Healthcare resource use and humanistic burden associated with attack frequency in episodic cluster headache |
Disclosure: Dr. Andrews has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Andrews holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Andrews was involved as an investigator. Dr. Andrews holds stock and/or stock options in Eli Lilly and Company.
|
Neuroimaging: Aging, Vascular and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Cognition predicted by brain biomarkers and demographic factors |
Disclosure: Dr. Tsapanou has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Late onset MS is associated with more severe longitudinal development of central brain atrophy compared to adult onset MS |
Disclosure: Dr. Dujmic has nothing to disclose.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Life Expectancy in Familial Cerebral Cavernous Malformation: An Analysis of Prospective Database |
Disclosure: Dr. Arsalan has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | PYGM mRNA Expression In Patients With McArdle Disease: Demographic, Clinical, Genetic And Morphological Correlations. |
Disclosure: Dr. Feder has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Long-term Outcomes in Patients with Intractable Mesial Temporal Lobe Epilepsy who Undergo Laser Ablation. |
Disclosure: Dr. Patel has nothing to disclose.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Burden of Spasticity Among Patients and Caregivers: Results of a Multinational Survey |
Disclosure: Dr. Patel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz and Allergan. Dr. Patel has received research support from Allergan, Merz, and Ipsen.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Gray Matter Atrophy in Parkinson’s Disease and Freezing of Gait Assessed Using Surface-Based Algorithm |
Disclosure: Dr. Kanovsky has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 019 | Sarcoidosis to Nocardiosis: An odyssey of doubt and agony |
Disclosure: Dr. Singh has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Medical Cannabis Treatment in Patients with Trigeminal Neuralgia |
Disclosure: Dr. Mechtler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, Promius, Allergan, Avanir, Amgen, Boston Biomedical, electroCore, Alder Biopharmaceuticals, Lilly. Dr. Mechtler has received research support from Dent Family Foundation.
|
Neuroimaging: Aging, Vascular and Other | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Increased Activity in Functional Brain Network among the Elderly with Youthful Memory in Superaging |
Disclosure: Dr. Chun has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Clinical Profile and functional outcomes of idiopathic inflammatory demyelinating disorders of CNS in adults. |
Disclosure: Dr. Gorthi has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Thyrotoxic Periodic Paralysis: An Unusual Presentation of Hyperthyroidism in a 20 year-old Male |
Disclosure: Dr. Smith has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Level Four Epilepsy Center Experience With Stereo-electroencephalography |
Disclosure: Dr. Podkorytova has nothing to disclose.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Economic evaluation of abobotulinumtoxinA vs onabotulinumtoxinA in real-life clinical management of post-stroke upper limb spasticity |
Disclosure: Dr. Danchenko has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | EEG-fNIRS Combined Neuroimaging Study on PD patients performing UPDRS Motor Tasks |
Disclosure: Dr. Abtahi has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 020 | Carbon Monoxide exposure, a red herring in a patient with rapidly progressive dementia, later diagnosed with Creutzfeldt-Jakob disease |
Disclosure: Dr. Pang has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Persistent Neurological Deficits in a Patient with Hemiplegic Migraine Revealing Diffuse Astrocytoma |
Disclosure: Dr. Suneja has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | The Neural Substrate of Memory Impairment in the Oldest old with Dementia; The 90+ Study |
Disclosure: Dr. Sajjadi has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Real Life Evidence for CSF Neurofilaments Light Chain in Clinical Practice. |
Disclosure: Dr. Carrillo-Loza has nothing to disclose.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | A Case of Dural A-V Fistula with Bilateral Thalamic Hyper-intensity |
Disclosure: Dr. Komal Kumar has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | A NOVEL COMPOUND HETEROZYGOUS MUTATION IN TITIN LEADS TO CORE MYOPATHY WITH HEART DISEASE |
Disclosure: Dr. Castoro has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Altered resting-state network topology in drug-naïve idiopathic generalized epilepsy |
Disclosure: Dr. Bin Kim has nothing to disclose.
|
Neuro-rehabilitation: From Mechanism to Treatment | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | A study on Affordable Rehabilitation Care in Developing Countries with Use of Low Cost Technologies |
Disclosure: Dr. Kokane has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Initial Long-term Treatment with Rotigotine Maintains Striatal Dopamine Transporter Binding in De Novo Patients with Parkinson Disease |
Disclosure: Dr. Ikeda has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 021 | Aortic Fungus Ball – An Unusual Cause of Paraplegia |
Disclosure: Dr. Natteru has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Hypnic Headache: Characteristics and Treatment Modalities in An Academic Headache Center |
Disclosure: Dr. Wax has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Multimodal Magnetic Resonance Imaging versus 18F-FDG-PET to Identify Mild Cognitive Impairment |
Disclosure: Dr. Dolui has nothing to disclose.
|
MS Metrics of Prognosis and Disease Progression | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Positive Predictive Value of Elevated Unique Cerebrospinal Fluid Oligoclonal Bands |
Disclosure: Dr. Farin has nothing to disclose.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Rapidly Progressive Cognitive Decline from a Dural AV Fistula |
Disclosure: Dr. Berth has nothing to disclose.
|
Genetic Muscle Disorders II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Diagnostic Challenges of Congenital Myopathies in the Adult Neuromuscular Clinic |
Disclosure: Dr. Nicolau has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Epilepsy MRI Interpretations Outside Of Comprehensive Epilepsy Centers Often Miss Epileptogenic Lesions |
Disclosure: Dr. Ortiz-Guerrero has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | One Hundred Years of Innovation: Automatic Detection of Brain Ventricular Volume using Deep Learning in a Large-Scale Multi-Institutional Study |
Disclosure: Dr. Han has nothing to disclose.
|
Parkinson's Disease: Animal Models and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping |
Disclosure: Dr. Huang has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 022 | Leprosy presenting as orofacial pain: case report. |
Disclosure: Dr. Macedo has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Sex-induced Headache Associated with Moyamoya Angiopathy: A Case Story and Literature Review |
Disclosure: Dr. Chen has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Clinical and Molecular PET Imaging Markers of Primary Progressive Aphasia due to Likely Alzheimer's Disease Pathology |
Disclosure: Dr. Roll has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Sex-specific Differences in Rim Appearance of Multiple Sclerosis Lesions on Quantitative Susceptibility Mapping |
Disclosure: Dr. Tolaymat has nothing to disclose.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Clinical and Radiographic Features of Multiple Intracranial Arteriovenous Malformations |
Disclosure: Dr. Chiu has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Incidence and Predictors of readmission in patients with Myasthenia Gravis: A National population-based cohort study (2010-14). |
Disclosure: Dr. Singh has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Epilepsy Surgery Outcomes in the setting of Encephalitis: A Case Series |
Disclosure: Dr. Spurgeon has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Abnormal DWI Signals of Spine in a Sporadic Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia caused by a novel c.1907T>A. Mutation in CSF1R |
Disclosure: Dr. Li has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | Barriers and Characteristics of Caregiving Preparedness in Parkinson’s disease: a qualitative approach |
Disclosure: Dr. Nwadiogbu has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 023 | The Mysterious Mold: A Case of Coccidioides Meningitis |
Disclosure: Dr. Slawski has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Diagnostic Delay in Patients Prior to Being Seen in Headache Clinic |
Disclosure: Dr. Puvvadi has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | The Relationship of Amyloid Beta in the Retina to that of the Brain is Burden-specific |
Disclosure: Dr. Bissig has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Demyelination, Inflammation and Axonal Loss Explain Different Patterns of Fractional Anisotropy Abnormalities in MS Cortical Normal Appearing Gray Matter and Lesions |
Disclosure: Dr. Preziosa has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis and ExceMED.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Is There Any Pivotal Association Between Smoking and Alpha-1 Antitrypsin Level and Function in Aneurysmal Subarachnoid Hemorrhage? |
Disclosure: Dr. Ansari has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | LEMS with Anti-VGCC Antibodies and Dermatomyositis with Anti-TIF1-Gamma Antibodies: A Unique Case Study of Concomitant Autoimmune Neuromuscular Conditions without Malignancy |
Disclosure: Dr. Isfort has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Hospital Readmissions After an Epilepsy Related Surgical Intervention in the Nationwide Readmissions Database |
Disclosure: Dr. Subramaniam has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Clinical and Radiographic Characterization of Synthetic Cannabinoid-induced Toxic Leukoencephalopathy |
Disclosure: Dr. Amar has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | What Bothers Parkinson Patients: Clinical Curation of their Verbatim Reports |
Disclosure: Dr. Arbatti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Grey Matter Technologies.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 024 | Unilateral Periorbital and Facial Swelling with Multiple Unilateral Cranial Nerve Deficits in an Uncontrolled Diabetic |
Disclosure: Dr. Dicken has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | One-Month Feasibility of Progressive Muscle Relaxation (PMR) via Smartphone Application for Post Traumatic Headache (PTH) Patients |
Disclosure: Dr. Usmani has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Diffusion Tensor Imaging in pre-dementia risk states: white matter atrophy findings in Mild Behavioral Impairment |
Disclosure: Dr. Gill has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | 3D MR image synthesis using unsupervised deep learning algorithm in MS patients |
Disclosure: Dr. Jabarzedeh has nothing to disclose.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Dynamic Cerebral Autoregulation and Personalized Blood Pressure Monitoring in Patients with Aneurysmal Subarachnoid Hemorrhage (aSAH) |
Disclosure: Dr. Silverman has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Response Rates in Placebo arm of MG Clinical Trials |
Disclosure: Dr. Muppidi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion Pharmaceuticals.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Epilepsy Surgery Trends In the United States, 2009–2014 |
Disclosure: Dr. Vellipuram has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Cocaine Use Associated with Bilateral Globus Pallidus Changes; Similar to Carbon Monoxide intoxication. |
Disclosure: Dr. Azeem has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | A Closer Look at the Unmet Needs, Research and Care Priorities for Women with Parkinson's |
Disclosure: Dr. Feeney has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 025 | Community-acquired Klebsiella pneumoniae meningitis. Questioning the demographic paradigm with new recommendations for diagnosis and effective treatment |
Disclosure: Dr. Michaelson has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Marijuana Use In Headache In a University–Based Headache Clinic |
Disclosure: Dr. Schorn has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Phenotypes and Biomarkers in Posterior Cortical Atrophy: Application of Consensus Clinical Diagnostic Criteria and the AT(N) Framework |
Disclosure: Dr. McGinnis has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | A comparison of FLAIR and T1 maps from MP2RAGE at 7T for quantifying lesion volume and its correlation to disability in multiple sclerosis |
Disclosure: Dr. Spini has nothing to disclose.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Endovascular Therapy Versus Clipping For Aneurysmal Subarachnoid Hemorrhage, 2004-2014 Trends |
Disclosure: Dr. Venkatraman has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Congenital Myasthenic Syndrome with A Novel Agrin Gene Mutation |
Disclosure: Dr. Giler has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Contralateral hippocampal atrophy after temporal lobe surgery: volumetric analysis of preoperative and long-term postoperative MRI |
Disclosure: Dr. Silva has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Capecitabine Induced Leukoencephalopathy: Is there a correlation with liver metastases? |
Disclosure: Dr. Ibrahim has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | SNCA G51D Missense Mutation Causing Juvenile Onset Parkinson’s Disease |
Disclosure: Dr. Cooper has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 026 | Pituitary Apoplexy Mimicking Meningoencephalitis: A Case Report and Literature Review |
Disclosure: Dr. Chu has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | A Survey Comparing Neurology and Internal Medicine Residents’ Approaches to Headache Management |
Disclosure: Dr. Cooper has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Correlates between functional connectivity and amyloid deposition in healthy controls |
Disclosure: Dr. Bruña has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Brainvestigations.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | New/Enlarging Lesion Count: Man versus Machine |
Disclosure: Dr. Van Hecke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with icometrix.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Early Elevation of Plasma Lipocalin-2/NGAL is Associated with Poor Neurofunctional Outcome in Subarachnoid Hemorrhage Patients |
Disclosure: Dr. Yu has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | The Diagnostic Yield of Repetitive Nerve Stimulation in Seropositive vs. Seronegative |
Disclosure: Dr. Hua has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | The Pathogenesis and A Novel Surgical Approach to Treating Drug-Resistant Status Epilepticus Associated with Neurocysticercosis |
Disclosure: Dr. Law has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Tacrolimus Induced Osmotic Demyelination in Patient with Liver Transplantation |
Disclosure: Dr. Pauta Martinez has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Levodopa Responsiveness Subtypes of Freezing of Gait: Results Using a Levodopa Test |
Disclosure: Dr. Factor has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Neurocrine, Lundbeck, Teva, Avanir, Sunovion, Adamas, Prexton, Biogen. Dr. Factor has received research support from Ipsen, Medtronics, Teva, US World Meds, Sunovion, Solstice, Vaccinex, Voyager, CHDI Foundation, Michael J. Fox Foundation, NIH.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 027 | Suboxone abuse with shared needle as a cause of Botulism in an IV drug user |
Disclosure: Dr. Roy has nothing to disclose.
|
Headache | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Undertreatment of Headache Associated with Sexual Activity |
Disclosure: Dr. Cuneo has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Association of Cortical and Subcortical Aß Deposition with Depressive and Anxiety Symptoms: A Population-based Cross-sectional Study |
Disclosure: Dr. Krell-Roesch has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Correlation Between Neurologic Challenge Task Performance and Lesion Localization of Sub-Threshold Lesions in Multiple Sclerosis Patients with EDSS Score of 0 |
Disclosure: Dr. Antoine has nothing to disclose.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Novel explanation of angular remodeling in stent assisted coiling (SAC) of bifurcation aneurysms: Is it the stent or the coils? |
Disclosure: Dr. Saied has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Efficacy and limitations of cyclophosphamide in refractory myasthenia gravis |
Disclosure: Dr. Garcia Trejo has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | VNS therapy vs. discontinuation of VNS therapy: Long-term seizure outcome |
Disclosure: Dr. Gill has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Is Acute Immunodeficiency Syndrome (AIDS) a risk factor for Central Pontine Myelinolysis (CPM). |
Disclosure: Dr. Zeb has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Altered Dopamine Transmission in Peripheral Mononuclear Cells in Parkinson's Disease |
Disclosure: Dr. Saadatpour has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 028 | Lyme disease presenting as multiple small cerebral infarcts of undetermined source. |
Disclosure: Dr. Alcantara Lima has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Functional brain connectome organization associated with atrophy and hypometabolism in posterior cortical atrophy |
Disclosure: Dr. Migliaccio has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Automatically segmented medulla oblongata volume as a surrogate for spinal cord atrophy in multiple sclerosis |
Disclosure: Dr. Bergsland has nothing to disclose.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Systematic Review of the Angiographic Evoluation of Neck Residual (Class II) Aneurysms |
Disclosure: Dr. Maud has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Assessment of disease severity in patients with Myasthenia Gravis – Clinical Phenotype and Immunological Correlation |
Disclosure: Dr. Garuda has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Patient selection and outcomes of placement of the Neuropace Responsive Neurostimulator for the treatment of intractable epilepsy: a single center experience |
Disclosure: Dr. Agostini has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Post-Mortem Neuroimaging in Amyotrophic Lateral Sclerosis |
Disclosure: Dr. Ishaque has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Incidence and Predictors of 30 days readmission associated with Parkinson’s disease: 5-year National estimate (2010-2014) |
Disclosure: Dr. Singh has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 029 | Sudden Death from Rupture of Cerebral Abscess into Subarachnoid Space |
Disclosure: Dr. Curran has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Tracking Neurostructural Preclinical Predictors of Alzheimer’s Disease: Linking Clinical Markers to the Size of the Ventral Tegmental Area and Other Subcortical Nuclei |
Disclosure: Dr. De Marco has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Inflammatory activity associated with increased rate of brain and retinal neuro-axonal injury in early MS The aim of this study is to address the effect of local inflammatory activity in brain and retinal neuro-axonal injury along MS course. |
Disclosure: Dr. Pulido Valdeolivas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche Spain, Genzyme-Sanofi, and Aura Innovative Robotics. Dr. Pulido Valdeolivas has received compensation for serving on the Board of Directors of Aura Innovative Robotics. Dr. Pulido Valdeolivas has received royalty, license fees, or contractual rights payments from Aura Innovative Robotics. Dr. Pulido Valdeolivas holds stock and/or stock options in Aura Innovative Robotics which sponsored research in which Dr. Pulido Valdeolivas was involved as an investigator. Dr. Pulido Valdeolivas holds stock and/or stock options in Aura Innovative Robotics. Dr. Pulido Valdeolivas has received research support from Aura Innovative Robotics.
|
Intracerebral Aneursym and Other Neurovascular Malformations | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Impact of daughter vessel selection for stent deployment on the recanalization rates of bifurcation aneurysms treated with single stent-assisted coiling (SAC) |
Disclosure: Dr. Saied has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Are the choices of Therapeutic options for the Management of Myasthenia Gravis Crisis with acute respiratory failure-Influenced by the patient’s Age. A New York State Planning and Research Cooperation System Database Analysis (1998-2014) |
Disclosure: Dr. Sheikh has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Effects of Low- Frequency Stimulation of Anterior Piriform Cortex on Memory in Epileptic Rats |
Disclosure: Dr. Bayat has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Evolution of Magnetic Resonance Signal Characteristics in Inferior Olivary Nuclei in Patients Presenting with Palatal Myoclonus Syndrome – Cases |
Disclosure: Dr. Manering has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | G2019S mutation and motor complications of levodopa in Parkinson disease |
Disclosure: Dr. Farhat has nothing to disclose.
|
Bacteria, Fungi, and Prions | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 030 | Paradoxical reaction in non-HIV patients with CNS tuberculosis: what, when and how? |
Disclosure: Dr. Dominguez-Moreno has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Location of Intracerebral Hemorrhage and Cause of Death in the Longitudinal Follow-up of ICH Survivors in ERICH (ERICH-L) Study |
Disclosure: Dr. Bakk has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | WMH Progression but not Regression is Associated with a Higher CSF tau/Aß and Temporal Amyloid Concentration in The Amyloid PET Scan |
Disclosure: Dr. Al-Janabi has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Investigation into the Relationship between Digital Brain Volume and Computerized Screening Assessment of Cognitive Function in People with Multiple Sclerosis: Objective Analytics to Quantify Disease Impact – Cross Sectional Relationship |
Disclosure: Dr. Srinivasan has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | A case of hepatocellular carcinoma presenting with myasthenia gravis |
Disclosure: Dr. Fussner has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Evaluating an Online Tool to Determine Appropriateness for Epilepsy Surgery Evaluation in Brazil |
Disclosure: Dr. Bianchin has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Magnetic Resonance Imaging-Based Evaluation of the Etiology of Non-traumatic Myelopathies in Bangladesh: A Hospital-based Observational Cross-sectional Study from Two Tertiary Care Centers of Dhaka. |
Disclosure: Dr. Shoab has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Changes in Prescribing Practices of Dopaminergic Medications in Individuals with Parkinson's Disease by Expert Care Centers From 2010 to 2017: The Parkinson's Foundation Quality Improvement Initiative (PF-QII) |
Disclosure: Dr. Dubaz has nothing to disclose.
|
Neurocysticercosis and Other Parasitic Infections | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 031 | Intramedullary spinal neurocysticercosis |
Disclosure: Dr. Manske has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Predictors and Associated Outcomes with Unanticipated Surgical Evacuation in Patients with Intracerebral Hemorrhage: Post Hoc Analysis of ATACH 2 Trial |
Disclosure: Dr. Qureshi has nothing to disclose.
|
Neuroimaging: Alzheimer Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Structural Brain Organization Associated with Gait in Mild Cognitive Impairment Subtypes |
Disclosure: Dr. Allali has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Quantitative Spinal Cord MRI in MS patients with Sexual Dysfunction: A Cross-sectional Study. |
Disclosure: Dr. Seyman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen-Idec. Dr. Seyman has received research support from Novartis.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Myasthenia Gravis Mimicking Stroke - Implications of Cognitive Errors and Clinical Factors |
Disclosure: Dr. Kukulka has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Early Use of Vagal Nerve Stimulation (VNS) in a Patient with New Onset Refractory Status Epilepticus (NORSE) |
Disclosure: Dr. Wong has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Diagnostic utility of hypoglossal canal MRI in uncovering an unusual cause of Isolated hypoglossal nerve palsy. |
Disclosure: Dr. Rayi has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Survival in Parkinson disease, the Trondheim cohort |
Disclosure: Dr. Hustad has nothing to disclose.
|
Neurocysticercosis and Other Parasitic Infections | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 032 | Neurocysticercosis in Qatar |
Disclosure: Dr. Shaheen has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | In-hospital Mortality, Resource Utilization and 30-Day Readmission among Patients with Intracerebral Hemorrhage Transferred to Centers with Higher Level of Care |
Disclosure: Dr. Bambhoroliya has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Clinical and Conventional MRI Predictors of Cognitive Rehabilitation Efficacy in Multiple Sclerosis |
Disclosure: Dr. Fuchs has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | High Prevelance Of Osteoporosis And Osteopenia In Adult Myasthenia Gravis Patients-A Pilot Study From An Academic Institution In Central Pennsylvania |
Disclosure: Dr. Bowling has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Combined Treatment of Bilateral Periventricular Nodular Heterotopia with Laser Ablation and Neuropace Leads Placement after Stereo-EEG Evaluation |
Disclosure: Dr. Podkorytova has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Chronic Vestibular Syndrome Associated with Anterior Inferior Cerebellar Artery loop into the Internal Acoustic Meatus |
Disclosure: Dr. Lawal has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Levodopa doses and improvement in LRRK2 G2019S carriers compared to non-carriers |
Disclosure: Dr. Farhat has nothing to disclose.
|
Neurocysticercosis and Other Parasitic Infections | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 033 | Brain eating Balamuthia amoebic infection – A Case Report |
Disclosure: Dr. Ballur Narayana Reddy has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | A cross sectional analytical study of cognitive impairment in survivors of spontaneous intracranial hemorrhage (ICH). |
Disclosure: Dr. Gorthi has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Integration and Characterization of Brain MRI Data from the Italian Neuroimaging Network Initiative (INNI) for the Study of Multiple Sclerosis |
Disclosure: Dr. Storelli has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Comparison of Clinical and Laboratory Features of Myasthenia Gravis in Different Ethnic, Gender and Age groups. |
Disclosure: Dr. Pakneshan has nothing to disclose.
|
Epilepsy: Surgery and Imaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Stereoelectroencephalography following grids and strips: case series of six patients |
Disclosure: Dr. Crowder has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Cerebral Venous Sinus Thrombosis Associated with Electroconvulsive Therapy Resulting in Dural Arteriovenous Fistula |
Disclosure: Dr. Al-Dulaimi has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Trend in PEG placement in Parkinson's disease compared to Alzheimer dementia and ALS |
Disclosure: Dr. Kim has nothing to disclose.
|
Neurocysticercosis and Other Parasitic Infections | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 034 | Spinal Schistosomiasis masquerading as an Intramedullary Astrocytoma |
Disclosure: Dr. Kvernland has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Hypervitaminosis E and a-tocopherol levels in Intracranial Hemorrhagic Stroke |
Disclosure: Dr. Le has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Cognitive Impairment and Deep Grey Matter Lesions on 7T MRI in Multiple Sclerosis |
Disclosure: Dr. Tomkinson has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Successful Rituximab Desensitization In Two Patients With Myasthenia Gravis |
Disclosure: Dr. Suh has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Clinical and radiographic mismatch in fat embolism syndrome in hemoglobin SC disease |
Disclosure: Dr. Moghbel has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | Endemic parkinsonism associated with the rare haplotype of LRRK2 gene |
Disclosure: Dr. Mensikova has nothing to disclose.
|
Neurocysticercosis and Other Parasitic Infections | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 035 | MRI findings and evolution of active or calcified cysts in treated and untreated patients with neurocysticercosis |
Disclosure: Dr. Monteiro has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Unusual intracerebral hemorrhagic (ICH) stroke presentation: Tumor to tumor metastasis. |
Disclosure: Dr. Alvarado Arias has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Cerebellar Volume Loss in Radiologically Isolated Syndrome |
Disclosure: Dr. George has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Volumetric Analysis and Densitiy of Extraocular Muscles in patients with Myasthenia Gravis |
Disclosure: Dr. Kohler has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Brainstem Posterior Reversible Encephalopathy Syndrome |
Disclosure: Dr. Sanmartin has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Case-based Medical Education Improves Neurologists’ Competence in Diagnosing and Managing Levodopa-induced Dyskinesia |
Disclosure: Dr. Martorano has nothing to disclose.
|
Neurocysticercosis and Other Parasitic Infections | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 036 | Neurotoxoplasmosis in Immunocompetent Patients Mimicking Lymphoproliferative Disease |
Disclosure: Dr. Ferreira Lima has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Simultaneous Ischemic stroke and Intracerebral Hemorrhage due to Amyloid Angiopathy presenting as a Therapeutic Challenge |
Disclosure: Dr. Amin has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Lower Total Cerebral Arterial Flow Contributes to Cognitive Performance in Multiple Sclerosis Patients |
Disclosure: Dr. Jakimovski has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Burden of Disease in Patients with Refractory Myasthenia Gravis |
Disclosure: Dr. Sharma has nothing to disclose.
|
General Neurology: Neuroimaging and Disease | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Creutzfeldt-Jakob Disease Associated Longitudinally Extensive Transverse Myelitis; a Rare Presentation Accompanied By Rapid Disease Progression |
Disclosure: Dr. Jordan has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | Risk Factors in Essential Tremors for the Development of Parkinson’s Disease vs Parkinsonism |
Disclosure: Dr. Lau has nothing to disclose.
|
Neurocysticercosis and Other Parasitic Infections | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 037 | New Diagnosed Active Neurocysticercosis: Serial Image Findings and Corresponding Clinical Manifestations |
Disclosure: Dr. Rafiuddin has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | A Case of Cerebral Amyloid Angiopathy Associated Primary Progressive Aphasia |
Disclosure: Dr. Pauta Martinez has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Increased Iron Accumulation in Red Nucleus, Spelium, Putamen and Thalamus in Multiple Sclerosis and CIS: A 7 Tesla MRI Study |
Disclosure: Dr. Kocer has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Nocebo In Myasthenia Gravis: A Systematic Review And Meta-Analysis Of Randomized Placebo-Controlled Trials |
Disclosure: Dr. Varma has nothing to disclose.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Novel Mutation in ACSL4 Gene Leading to X-linked Intellectual Disability, Autism and ADHD |
Disclosure: Dr. Gupta has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | Oral cavity disorders in Parkinson’s disease: more than meets the eye |
Disclosure: Dr. Auffret has nothing to disclose.
|
Neurocysticercosis and Other Parasitic Infections | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 038 | An Unusual Radiographic Feature of Toxoplasma Encephalitis in Renal Transplant Recipient |
Disclosure: Dr. Sugianto has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Similarities and Differences in Intracerebral Hemorrhage Risk Factors by Race/Ethnicity |
Disclosure: Dr. Kittner has nothing to disclose.
|
Neurocritical Care: Subarachnoid Hemorrhage | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Validation of the original FRESH score in patients with subarachnoid hemorrhage |
Disclosure: Dr. Witsch has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Loss of intrathalamic tissue integrity in pediatric-onset multiple sclerosis measured with DTI. |
Disclosure: Dr. Datta has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Retrospective longitudinal assessment of MG-ADL score with treatment of myasthenia gravis |
Disclosure: Dr. Varon has nothing to disclose.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | Evaluation of Dystonia and Dystonic Posturing in a cohort of patients with autism spectrum disorder (ASD) |
Disclosure: Dr. Ray has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 039 | MANAGE-PD: A clinician-reported tool to identify patients with Parkinson's Disease inadequately controlled on oral medications – Results from vignette-based validation |
Disclosure: Dr. Antonini has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia, Sunovion, UCB, Boston Scientific, Angelini, Medtronic, GE, Boehringer Ingelheim, AbbVie, Zambon. Dr. Antonini has received research support from Mundipharma.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Mortality and Long Term Outcome after Spontaneous Intracerebral Hemorrhage |
Disclosure: Dr. Mguidich has nothing to disclose.
|
Neurocritical Care: Subarachnoid Hemorrhage | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Role of Systemic Inflammatory Response Syndrome (SIRS) in Subarachnoid Hemorrhage (SAH) Outcome |
Disclosure: Dr. Pandya has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Impact of Cervical Stenosis on Multiple Sclerosis Lesion Distribution in the Spinal Cord |
Disclosure: Dr. Gratch has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Clinical and demographic features of LRP4 positive myasthenia gravis patients |
Disclosure: Dr. Pesala has nothing to disclose.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Genetic test results for 523 patients with ASD/ID: The diagnostic yield of multigene analysis (Autism/ID Xpanded test) is higher than conventional first-tier tests, such as FMR1 repeat analysis and chromosomal microarray |
Disclosure: Dr. Shanmugham has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GeneDx.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 040 | Comorbidity and Polypharmacy in Parkinson's disease: comparative study with control group. Results from the COPPADIS Study Cohort. |
Disclosure: Dr. Avila-Rivera has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | Primary Occipital Lobar Hemorrhages Associated with Lower 1 Year Mortality |
Disclosure: Dr. Pan has nothing to disclose.
|
Neurocritical Care: Subarachnoid Hemorrhage | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | Early uptrending white blood cell count can be a predictor of poor outcome in patients with aneurysmal subarachnoid hemorrhage |
Disclosure: Dr. Azher has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | MS patients with low central vein sign frequency can be identified by FLAIR* MRi sequences |
Disclosure: Dr. Azzolini has nothing to disclose.
|
Neuromuscular Junction Disorders | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | Elevated Antiganglioside Antibodies in a Case of Paraneoplastic Neuromuscular Junction Disorder |
Disclosure: Dr. Jazebi has nothing to disclose.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | "Tell me with whom you walk, and I will tell you who you are”: A Social Network Analysis of Adolescents with ADHD |
Disclosure: Dr. Arruda has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 041 | Molecular and Genetic Characterization of Parkinson’s Disease: A Center-Wide Approach. |
Disclosure: Dr. Tropea has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Medtronics. Dr. Tropea has received research support from Sanofi.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 042 | Role of Anti-Platelets & Anti-coagulants in Intracerebral hemorrhage: Analysis of a Large National Database |
Disclosure: Dr. Suriya has nothing to disclose.
|
Neurocritical Care: Subarachnoid Hemorrhage | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 042 | Variability In Reported Physician Practices For Brain Death Determination |
Disclosure: Dr. Braksick has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 042 | Instrumental, Clinical, and Patient Reported Sensorimotor Correlates of Spinal Cord Grey and Total Cord Areas |
Disclosure: Dr. Alexander has nothing to disclose.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 042 | Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism status does not predict serum folate and B12 in children with Attention-Deficit/Hyperactivity Disorder (ADHD) |
Disclosure: Dr. Silverstein has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 042 | Novel Assistive Dress Shoe & Footwear Needs Analysis for Patients with Parkinson's Disease |
Disclosure: Dr. Sayadi has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 043 | Hemoglobin A1c in Intracerebral Hemorrhage: A Cross-sectional Analysis of a Large National Database. |
Disclosure: Dr. Farooqui has nothing to disclose.
|
Neurocritical Care: Subarachnoid Hemorrhage | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 043 | Prediction of QTc interval prolongation using aneurysm location and bleeding pattern in aneurysmal subarachnoid hemorrhage. |
Disclosure: Dr. Kinariwala has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 043 | Functional Connectivity with the Default Mode Network Predicts Efficacy of Cognitive Rehabilitation in People with Multiple Sclerosis |
Disclosure: Dr. Bartnik has nothing to disclose.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 043 | Methylenetetrahydrofolate Reductase (MTHFR) C677T polymorphism and associated vitamin D levels in children with Attention-Deficit/Hyperactivity Disorder (ADHD) |
Disclosure: Dr. Silverstein has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 043 | Parkinsonian patients experiences operating the computer with their eyes: the MAMEM project. |
Disclosure: Dr. Bostantjopoulou-Kambouroglou has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 044 | A Unique Case of Cavum Veli Interpositum Hemorrhage in an Adult |
Disclosure: Dr. Kaur has nothing to disclose.
|
Neurocritical Care: Subarachnoid Hemorrhage | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 044 | Radiological Severity Determines Glycemic Burden In Aneurysmal Subarachnoid Hemorrhage And Patient Outcome |
Disclosure: Dr. Shujaat has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 044 | Magnetization Transfer Saturation Reveals Subclinical Optic Nerve Demyelination in Pediatric Multiple Sclerosis |
Disclosure: Dr. Longoni has nothing to disclose.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 044 | A Prospective Open-label Trial of Long-Acting Liquid Methylphenidate for the Treatment of Attention Deficit/Hyperactivity Disorder in Intellectually Capable Adults with Autism Spectrum Disorder |
Disclosure: Dr. Joshi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Governor's Council for Medical Research and Treatment of Autism, The Israeli Society for ADHD, Canadian Academy of Child and Adolescent Psychiatry, University of Juelich. Dr. Joshi has received personal compensation in an editorial capacity for NIMH. Dr. Joshi has received research support from Pfizer Inc., F. Hoffmann-La Roche Ltd., NIH-NIMH, Simons Center for the Social Brain.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 044 | Jumping as a Strategy to Overcome Freezing of Gait while Turning in Parkinson’s Disease |
Disclosure: Dr. Lizarraga has nothing to disclose.
|
Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 045 | Validation of ICH and ICH-GS scores in cohort of Indian patients with Intracerebral hemorrhage |
Disclosure: Dr. Malapur has nothing to disclose.
|
Neurocritical Care: Subarachnoid Hemorrhage | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 045 | Predictors of 30-day readmissions and in-hospital mortality amongst patients admitted with aneurysmal subarachnoid hemorrhage-Insights from National Database |
Disclosure: Dr. Kara has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 045 | Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: a case-controlled magnetization transfer ratio study |
Disclosure: Dr. Dwyer has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Serono Novartis and Claret Medical. Dr. Dwyer has received research support from Novartis and Celgene.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 045 | Disparities in the Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents - a Nationwide Study |
Disclosure: Dr. Arruda has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 045 | Non-invasive Assessment of Dysphagia in Degenerative Disorder (Parkinson’s Disease) |
Disclosure: Dr. Gudwani has nothing to disclose.
|
Neurocritical Care: Subarachnoid Hemorrhage | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 046 | Decreased Odds for Vasospasm Treatment in Patients with Aneurysmal Subarachnoid Hemorrhage After Transitioning from Neurosurgery-Led Care to a Neurology-Led Multidisciplinary Approach |
Disclosure: Dr. Bartt has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 046 | Correlation between Magnetization Transfer Ratio and Functional Status in Multiple Sclerosis patients |
Disclosure: Dr. Ebrahim has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 046 | Early Ischemic Changes on Serial CT Imaging in Acute Ischemic Stroke |
Disclosure: Dr. Czap has nothing to disclose.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 046 | Novel Research Initiatives for Early Recognition and Comprehensive Management of Autism Spectrum Disorder to Empower Health Professionals and Health Care Providers: Two Decade Experience from a Tertiary Care Centre in India |
Disclosure: Dr. Panda has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 046 | Vitamin D Assessment in Veterans with Parkinson’s Disease |
Disclosure: Dr. Jamal has nothing to disclose.
|
Neurocritical Care: Subarachnoid Hemorrhage | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 047 | Role of Glycemic Burden and Glycemic Burden Variability in Determination of Temporary and Permanent Cerebrospinal Fluid diversion after Aneurysmal Subarachnoid Hemorrhage |
Disclosure: Dr. Muzammil has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 047 | Dynamics of Pseudo-Atrophy in RRMS Patients Treated with Interferon beta-1a as Assessed by Monthly Brain MRI |
Disclosure: Dr. De Stefano has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Serono S.A., Teva Pharmaceutical Industries, Novartis Pharma AG, BayerSchering AG, SanofiAventis and Serono Symposia International Foundation.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 047 | The Absence of Collaterals is Associated with Larger Infarct Volume and Worse Outcome |
Disclosure: Dr. Kimmel has nothing to disclose.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 047 | Health Care Transition and Longitudinal Care for Adolescents and Young Adults with Hydrocephalus |
Disclosure: Dr. Williams has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 047 | Impact of Parkinson’s Disease on Faith and Spirituality - a Comparative Study |
Disclosure: Dr. Worku has nothing to disclose.
|
Neurocritical Care: Subarachnoid Hemorrhage | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 048 | Lactococcus garvieae endocarditis with an initial presentation of subarachnoid hemorrhage |
Disclosure: Dr. Purushothaman Ravichandran has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 048 | Resting-state functional correlates of Social Cognition in Multiple Sclerosis |
Disclosure: Dr. Bisecco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Merck.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 048 | To CTA or Not to CTA: Should We Continue to Order CT Angiography of Head and Neck in Patients with TIA? |
Disclosure: Dr. Bach has nothing to disclose.
|
Child Neurology: Autism and Behavioral Neurology | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 048 | Assessing Effectiveness of an Educational Intervention on Gaps in Child Neurology Knowledge for Pediatric Residents |
Disclosure: Dr. Rahman has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 048 | Prevalence and clinical correlates of metabolic syndrome in patients with Parkinson’s disease. |
Disclosure: Dr. Meléndez-Flores has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 049 | Cortical Thickness, Subcortical Volumes and Disability in Multiple Sclerosis: A Prospective Longitudinal Study |
Disclosure: Dr. Kakara has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 049 | Tissue Based Selection for Large Vessel Occlusion Thrombectomy Leads to Similar Functional Outcomes in Conventional (0-6 hours) and Extended (>6 hours) Window |
Disclosure: Dr. Bhan has nothing to disclose.
|
Child Neurology: Epilepsy II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 049 | In Silico Predictions of KCNQ Channel Variant Pathogenicity in Epilepsy |
Disclosure: Dr. Ritter has nothing to disclose.
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 049 | Sporadic Parkinson's Disease and Amyotrophic Lateral Sclerosis: A New Syndrome? |
Disclosure: Dr. Puri has nothing to disclose.
|
Neurocritical Care: Brain Death and Traumatic Brain Injury | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 049 | Epidemiological Factors Influencing Organ Donation Following Brain Death |
Disclosure: Dr. Green has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 050 | Nystagmus-associated imaging signatures in Multiple Sclerosis: evaluation of subcortical and infratentorial structures |
Disclosure: Dr. Bede has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 050 | Underestimation of Ischemic Core on Perfusion CT in Patients with Acute Large Vessel Occlusion: Results from the BEST Prospective Cohort Study |
Disclosure: Dr. Siegler has nothing to disclose.
|
Child Neurology: Epilepsy II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 050 | Correlations between genetic, biochemical, and clinical characteristics in glucose transporter 1 deficiency syndrome: a single-center study. |
Disclosure: Dr. Nabatame has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB Japan Co Ltd., Eisai Co. Ltd., Otsuka pharmaceutical Co., Shindan to Chiryo Sha. Dr. Nabatame has received research support from Eisai Co., Otsuka pharmaceutical Co., UCB Japan, Meiji Seika Pharma Co., Alfresa Co., Takeda Pharmaceutical Co., Biogen Japan, Japan Blood Products Organization, Kyowa Hakko Kirin Co..
|
Parkinson's Disease Clinical Features and Clinical Care II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 050 | Exploring the Experience of Wearing Off in Parkinson’s Disease: A Qualitative Research Approach |
Disclosure: Dr. Chahine has nothing to disclose.
|
Neurocritical Care: Brain Death and Traumatic Brain Injury | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 050 | Two Cases of Fulminant Acute Motor and Sensory Axonal Neuropathy Mimicking Brain Death |
Disclosure: Dr. Rodrigo has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 051 | Spine atrophy and sensory-motor disability in African Americans with Multiple Sclerosis |
Disclosure: Dr. El Mendili has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 051 | Computed Tomography Perfusion Imaging in Evaluation of Patients With Acute Stroke is Not Associated With Increased Risk of Acute Kidney Injury |
Disclosure: Dr. Satkowiak has nothing to disclose.
|
Child Neurology: Epilepsy II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 051 | Clinical Decision Support to Promote SUDEP Discussions |
Disclosure: Dr. Downs holds stock and/or stock options in Digital Health Solutions, LLC. Dr. Downs has received research support from Digital Health Solutions, LLC.
|
Neurocritical Care: Brain Death and Traumatic Brain Injury | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 051 | Bobbing-Like Ocular Movements in a Patient with Brain Death |
Disclosure: Dr. McDaniel has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 052 | Influence of T2-Hyperintense Lesions on Cervical Spinal Cord Atrophy and Disability in Patients with Multiple Sclerosis |
Disclosure: Dr. Rocca has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, Teva, Merck Serono, and Roche.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 052 | Computed Tomography Perfusion provides clinically relevant core infarct for thrombectomy selection |
Disclosure: Dr. Shaker has nothing to disclose.
|
Child Neurology: Epilepsy II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 052 | Evolution of Dietary Therapies in Treatment of Childhood Drug Resistant Epilepsy: an overview of nine studies including six randomized controlled trials accomplished over last twelve years in a tertiary care teaching hospital in North India |
Disclosure: Dr. Gulati has nothing to disclose.
|
Neurocritical Care: Brain Death and Traumatic Brain Injury | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 052 | End of Life Preferences: Medical Students’ Attitudes Toward Life Support |
Disclosure: Dr. Zhong has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 053 | Changes in Brain Volume in Specific Regions could be related to Disability Progression in Primary Progressive Multiple Sclerosis Patients |
Disclosure: Dr. Perez Miralles has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 053 | Clinical and imaging features of contrast induced neurotoxicity after cerebral angiography – Case series |
Disclosure: Dr. Zevallos has nothing to disclose.
|
Child Neurology: Epilepsy II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 053 | Safety Education by Frontline Providers in Pediatric Patients with Suspected Seizures |
Disclosure: Dr. Freedman has nothing to disclose.
|
Neurocritical Care: Brain Death and Traumatic Brain Injury | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 053 | Outcomes in Neurologically Critically Ill Patients with Fixed Dilated Pupils: A Retrospective Cohort Study |
Disclosure: Dr. Kornspun has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 054 | Is there a relationship between Incidental Learning and Self-temporal Projection in relapsing remitting multiple sclerosis patients? |
Disclosure: Dr. Rodrigo has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 054 | Ischemic Stroke Subtyping, Based on Vascular Imaging: A University Hospital Based Study |
Disclosure: Dr. Shahidullah has nothing to disclose.
|
Child Neurology: Epilepsy II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 054 | Late-onset Rasmussen encephalitis: Diagnosis Difficulty |
Disclosure: Dr. Sansa has nothing to disclose.
|
Neurocritical Care: Brain Death and Traumatic Brain Injury | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 054 | The Successful Implementation of a TBI Brain Donation Pathway |
Disclosure: Dr. Silverman has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 055 | Resting State Network Functional Connectivity Abnormalities in Systemic Lupus Erythematosus: Correlations with Neuropsychological and Neuropsychiatric Variables |
Disclosure: Dr. Bonacchi has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 055 | Focal Parietal Lobe Atrophy in Antiphospholipid Syndrome: Retrospective Analysis |
Disclosure: Dr. Wong has nothing to disclose.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 055 | Mesenchymal Stem/Stromal Cell Therapy during Pediatric Cardiac Surgery on Neurogenesis in the Porcine Subventricular Zone |
Disclosure: Dr. Kapani has nothing to disclose.
|
Neurocritical Care: Brain Death and Traumatic Brain Injury | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 055 | Characterization of acute traumatic cerebral venous sinus thrombosis |
Disclosure: Dr. Schwartz has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 056 | Gray Matter Volume Loss Is Increased in Younger Patients With Relapsing Multiple Sclerosis but Minimized by Ozanimod: Experience From the Ozanimod Phase 3 Program |
Disclosure: Dr. Schippling has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck, Sanofi.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 056 | Hazy DWI Restriction in Pons on Hyperacute MRI: DWI 'Smog Sign’ |
Disclosure: Dr. Ikram has nothing to disclose.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 056 | Novel In Vivo Model of Prenatal Hypoxic Injury and Genetic Mitochondrial Hyposufficiency |
Disclosure: Dr. Cristancho has nothing to disclose.
|
Neurocritical Care: Brain Death and Traumatic Brain Injury | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 056 | Implementation of Attending-Supervised IPASS Handoffs in the Neuro-ICU |
Disclosure: Dr. Cifrese has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 057 | Utility of Digital Ophthalmoscope in Neurology Residency |
Disclosure: Dr. Chima has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 057 | Deep learning enables thalamic atrophy measurement on clinical quality T2 FLAIR images |
Disclosure: Dr. Dwyer has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Serono Novartis and Claret Medical. Dr. Dwyer has received research support from Novartis and Celgene.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 057 | Cardiovascular and metabolic risk factors for the development of cerebral small vessel disease: Longitudinal FLAIR imaging in the Mayo Clinic Study of Aging |
Disclosure: Dr. Scharf has nothing to disclose.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 057 | Estrogen receptor GPR30 is participated in the long-term adverse effect of neonatal dexamethasone treatment in female rats |
Disclosure: Dr. Lo has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 058 | Does Non-automated Phone Call Notification Improve No-Show Rates in Neurology Resident Clinic? |
Disclosure: Dr. Alshammaa has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 058 | Brain Volume Loss and Cognition in Teriflunomide-Treated Patients in TEMSO |
Disclosure: Dr. Wuerfel has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Biogen Novartis Roche.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 058 | Imaging of angiogenesis in white matter hyperintensities using simultaneous 68Ga-NOTA-PRGD2 PET/MRI |
Disclosure: Dr. Ding has nothing to disclose.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 058 | Sleep Disturbances in Pediatric Intracranial Hypertension |
Disclosure: Dr. Kornbluh has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 059 | Gender disparities in course speakers at the AAN Annual Meeting |
Disclosure: Dr. Figurelle has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 059 | Effect of Treatment Naiveté on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS |
Disclosure: Dr. Hunter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Acorda Therapeutics, Actelion, Adamas, Avanir, Bayer HealthCare, Novartis, Osmotica, Roche/Genentech, Sanofi-Genzyme and Teva Neuroscience. Dr. Hunter has received research support from Actelion, Adamas, Avanir, Bayer HealthCare, Novartis, Roche/Genentech, Sanofi-Genzyme and Teva .
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 059 | Case Report: Sonographic demonstration of a perfusion dependent stroke with negative MRI and a flow limiting stenosis |
Disclosure: Dr. Gomez has nothing to disclose.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 059 | Neurocognitive outcomes and their Diffusion Tensor Imaging (DTI) correlates in children with Mild Traumatic Brain Injury (mTBI) |
Disclosure: Dr. Madaan has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 060 | Perception of Futile Provision of Care among Clinicians in the Neurointensive Care Unit |
Disclosure: Dr. Chalela has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 060 | Magnetic Resonance Imaging Measures as Prognostic Parameters for Physical and Cognitive Outcomes up to 8 Years in Patients with Relapsing Forms of Multiple Sclerosis |
Disclosure: Dr. Vollmer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Academic CME, Alcimed, Anthem Blue Cross, Genentech/Roche, Biogen IDEC, Novartis, CellGene, Epigene, Rocky Mountain MS Center, GLG Consulting, Ohio Health, TG Therapeutics, Topaz Therapeutics, Dleara Lawyers, Teva. Dr. Vollmer has received research support from Teva, NIH/NINDS, Rocky Mountain MS Center, Actelion, Roche/Genentech, UT Southwestern, TG Therapeutics.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 060 | Transcranial Doppler-detected Microembolic Signals as a Predictor of New Brain Ischemic Lesion after Elective Coronary Intervention |
Disclosure: Dr. Herzig has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer. Dr. Herzig has received personal compensation in an editorial capacity for Ambit Media.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 060 | Neurologic Sequelae of Infective Endocarditis in Children |
Disclosure: Dr. Favilla has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 061 | Impact of doing Echocardiogram and Brain Magnetic Resonance Imaging on Length of Stay and Hospital Charges in Transient Ischemic Attack Patients in United States: Analysis of Nationwide Inpatient Sample 2006-2014 |
Disclosure: Dr. Bandaru has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 061 | Regional Myelin-Specific MRI Abnormalities in Susac Syndrome Suggests Demyelination is a Pathologic Feature |
Disclosure: Dr. Johnson has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 061 | Subclinical peripheral arterial disease in patients with acute ischemic stroke; study with an ultrasonography |
Disclosure: Dr. HA has nothing to disclose.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 061 | Favorable Outcome in Children and Adults with PRES despite Clinical and Radiological Differences |
Disclosure: Dr. Young has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 062 | Regional Variation in Medicare Part D Drug Spending Amongst Neurologists |
Disclosure: Dr. De Havenon has received research support from AMAG Pharmaceuticals and Regeneron Pharmaceuticals.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 062 | Long-Term Monitoring Of Brain Volume Loss In Multiple Sclerosis |
Disclosure: Dr. Pawlak has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Roche.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 062 | The Perplexing Texting of Dystextia – Whynn th Mesrage Indcates Thar Is A Probm |
Disclosure: Dr. Anderson has nothing to disclose.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 062 | Fetal Pain: A Review of Available Evidence |
Disclosure: Dr. Berns has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 063 | AAN Axon Registry: Limitation and Barriers to Optimal Participation and Performance at an Academic center |
Disclosure: Dr. Garg has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 063 | Atrophied T2 lesion volume and cognitive outcomes in multiple sclerosis |
Disclosure: Dr. Tavazzi has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 063 | Acute anterior thalamic infarcts affecting Memory and Cognition- an important but less well known lacunar syndrome |
Disclosure: Dr. Nandanwar has nothing to disclose.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 063 | Psychogenic Gait Disorder Complicating Recovery after Concussion: A Case Series |
Disclosure: Dr. Otallah has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 064 | A Survey of Attitudes Towards Genetic Testing in Amyotrophic Lateral Sclerosis (ALS) |
Disclosure: Dr. Xiao has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 064 | Global and regional brain atrophy in highly active MS-A biomarker for therapy switch |
Disclosure: Dr. Raji has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Serono, Genzyme, Novartis. Dr. Raji has received research support from Genzyme.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 064 | Lesion Topography and Its Correlation with Etiology in Medullary Infarction: Analysis from a Multi-Center Stroke Study in China |
Disclosure: Dr. Hong has nothing to disclose.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 064 | Kernicterus in the 21st Century: Bilirubin-Induced Brain Injury Due to Glucose-6-Phosphate Dehydrogenase Deficiency |
Disclosure: Dr. Chen has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 065 | Use of a Philadelphia Specific Spanish Toolkit in the neurology outpatient clinic in Temple University Hospital |
Disclosure: Dr. Jacobson has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 065 | Myelinating Proteins in MS are Linked to Volumetric Brain MRI changes |
Disclosure: Dr. Brod has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 065 | Bilateral Medial Medullary Syndrome with Atypical Clinical Presentation and Brain MRI Findings |
Disclosure: Dr. Farooqui has nothing to disclose.
|
Injury in Developing Brain: Fetal Neurology, Trauma and Stroke | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 065 | Caffeine Augments Anesthesia Neurotoxicity in the Fetal Macaque Brain |
Disclosure: Dr. Noguchi has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 066 | Trigeminal nerve root enhancement in multiple sclerosis |
Disclosure: Dr. Rukmangadachar has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 066 | Floating Heads: An Occi-dental Discovery of Bálint Syndrome |
Disclosure: Dr. Rathnam has nothing to disclose.
|
Child Neurology: Neuromuscular Disease: Birth to Adulthood II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 066 | Strengthening knowledge when data are scarce: the role of social media after AFM. |
Disclosure: Dr. Bove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Roche Genentech, Novartis, EMD Serono, Biogen, Sanofi Genzyme, and Pear Digital. Dr. Bove has received research support from Akili Interactive.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 067 | Transition of Care from Child to Adult Neurologists: Implementation and Financial Strategies for Child and Adult Neurologists |
Disclosure: Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Stealth Biotheraputics, Modis (aka Meves) Pharmaceuticals, NeuroVive, MitoBridge, AAN for CPT Consulting and Educational Activities. Dr. Cohen has received research support from Dr. Cohen has received research support from Stealth Biotherapeutics, BioElectron Technologies.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 067 | Short-term MRI-based Prediction of Clinical MS Progression in a Real World Setting |
Disclosure: Dr. Van Hecke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with icometrix.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 067 | Novel Neuroimaging Pattern In A Patient With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts And Leukoencephalopathy |
Disclosure: Dr. Petrea has nothing to disclose.
|
Child Neurology: Neuromuscular Disease: Birth to Adulthood II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 067 | A Case of Rapidly Progressive Juvenile-Onset Amyotrophic Lateral Sclerosis with a rare SOD1 genetic variant |
Disclosure: Dr. De La Torre Ribadeneira has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 068 | Challenges with the use of Prehospital Stroke Scales for early identification of Large Vessel Occlusion Strokes. |
Disclosure: Dr. Rahangdale has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 068 | The Effect of Glitiramer Acetate 40mg TIW on Multiple Brain MRI Parameters over One Year |
Disclosure: Dr. Rube has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 068 | Transient Smartphone Blindness: An Unusual Cause of Vision Loss in the 21st Century |
Disclosure: Dr. Rondeau has nothing to disclose.
|
Child Neurology: Neuromuscular Disease: Birth to Adulthood II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 068 | Stiff Person Syndrome: An Elusive Diagnosis in a Pediatric Patient |
Disclosure: Dr. Tuttrup has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 069 | Establishing a resident-led lumbar puncture clinic to improve resident satisfaction and skills during neurology residency |
Disclosure: Dr. Sader has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 069 | Thalamic nuclei volumes as markers of clinical disability and cognitive dysfunction in multiple sclerosis |
Disclosure: Dr. Bergsland has nothing to disclose.
|
Cerebrovascular Disease and Interventional Neurology: Imaging and Localization | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 069 | Non-invasive Longitudinal Assessment of Cerebrovascular Reactivity after TBI using functional Near Infrared Spectroscopy |
Disclosure: Dr. Sangobowale has nothing to disclose.
|
Child Neurology: Neuromuscular Disease: Birth to Adulthood II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 069 | Early onset congenital myopathies and LGMD phenotype investigated by muscle MRI in two trasportinopathy families |
Disclosure: Dr. Marozzo has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 070 | Contribution towards Public Health Awareness Activities and Continuing Medical education for Empowering Health Care Professionals on Childhood Neurodevelopmental Disorders: Experience of a Tertiary Care Teaching Hospital in North India over the last decade-Going E-way |
Disclosure: Dr. Panda has nothing to disclose.
|
MS Neuroimaging | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 070 | Volume Loss in Deep Gray Matter and Thalamic Sub-Nuclei in Placebo-treated Patients with Multiple Sclerosis in the Phase 3 TEMSO Study |
Disclosure: Dr. Magon has nothing to disclose.
|
Child Neurology: Neuromuscular Disease: Birth to Adulthood II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 070 | Juvenile Myasthenia Gravis: Evaluation of presentation and treatment outcomes in a large cohort |
Disclosure: Dr. Gill has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 071 | Perceptions of Preventive Stroke Care Received by Women in Different Primary Care Settings |
Disclosure: Dr. Atlas has nothing to disclose.
|
Immunotherapies: New Targets and Side Effects | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 071 | Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. |
Disclosure: Dr. Graf has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 072 | Strategies to Decrease Post Hospital Discharge Negative Outcomes for Patients with Neurological Diseases. |
Disclosure: Dr. Smith has nothing to disclose.
|
Immunotherapies: New Targets and Side Effects | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 072 | Naturally Occurring Anti-Neuronal Antibodies within IVIg Preparations: Importance in Clinical Practice |
Disclosure: Dr. Dimitriadou has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 073 | Quality Improvement in Laboratory Analysis of Paraneoplastic Panels |
Disclosure: Dr. Bajaj has nothing to disclose.
|
Immunotherapies: New Targets and Side Effects | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 073 | Isoagglutinin Reduction In IVIG By Specific Immunoaffinity Chromatography Reduces Spontaneous Reporting Rates Of Hemolytic Reactions |
Disclosure: Dr. Shebl has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with CSL Behring GmbH.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 074 | Improving Patient Return to Residency Clinic using a Patient Portal: A Residency Quality Improvement Project |
Disclosure: Dr. Kyrtsos has nothing to disclose.
|
Immunotherapies: New Targets and Side Effects | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 074 | Adrenal Insufficiency and Multiorgan Failure in a Patient Receiving Alemtuzumab Therapy |
Disclosure: Dr. Miller has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 075 | Evaluation of the Duke Neurology Advanced Practice Provider Training Program |
Disclosure: Dr. Morgenlander has nothing to disclose.
|
Immunotherapies: New Targets and Side Effects | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 075 | Long-term efficacy of intravenous immunoglobulin treatment in 49 patients with chronic inflammatory demyelinating polyradiculoneuropathy |
Disclosure: Dr. Seybold has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 076 | Effects of a novel practice model on medical team burnout in an academic neurology practice |
Disclosure: Dr. Kern has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Pharmaceuticals, Merz Pharma and SAI-Med Partners, LLC.
|
Immunotherapies: New Targets and Side Effects | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 076 | Analysis of Relapse by MRC Sum Score in the PATH Study of Subcutaneous Immunoglobulin in CIDP |
Disclosure: Dr. Bril has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with CSL Behring UCB Alnylam Argenx Alexion Grifols Octapharma Shire (Takeda) Pfizer and PowellMansfield. Dr. Bril has received research support from CSL Behring UCB Grifols Argenx Biogen and Octapharma.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 077 | Improving neurologists’ adherence to guidelines on prevention of possible complications of systemic corticosteroid therapy |
Disclosure: Dr. Samara has nothing to disclose.
|
Immunotherapies: New Targets and Side Effects | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 077 | The effect of oral Steriods in Chronic Demyelinating Polyneuropathy associated with Diabetes Mellitus |
Disclosure: Dr. Singh has nothing to disclose.
|
Practice, Policy, and Ethics II | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 078 | First Year Experience at SAC Health System, the First Federally Qualified Health Center (FQHC) Based Neurology Clinics |
Disclosure: Dr. Baker has nothing to disclose.
|
Immunotherapies: New Targets and Side Effects | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 078 | Treatment Satisfaction and Work Productivity in a Clinical Study of IgPro20 Maintenance Treatment of CIDP |
Disclosure: Dr. Hartung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer Healthcare, Biogen, Geneuro, Genzyme, Medimmune, Merck, Receptos Celgene, Novartis, Roche, CSL Behring.
|
11:30 AM | 079 | RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration |
Disclosure: Dr. Collins has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roivant Sciences, Inc; Immunovant, Inc.
|
11:30 AM | 080 | Changes in Concomitant Immunosuppressive Therapy Use During a Phase 3 Open-label Study of Eculizumab in Adults with Generalized Myasthenia Gravis: an Interim Analysis |
Disclosure: Dr. Nowak has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Ra Pharma, Momenta, Grifols, Roivant. Dr. Nowak has received research support from Alexion, Ra Pharma, Genentech, Grifols.
|
11:30 AM | 081 | Molecular Characterization of VEGF Secretion by MSC-NTF Cells (NurOwn®): Therapeutic Implications in ALS |
Disclosure: Dr. Kaspi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics.
|
11:30 AM | 082 | Saturation of alpha4 integrin (CD49d) in patients undergoing treatment with natalizumab in extended interval dose. |
Disclosure: Dr. Zhu has received research support from Biogen (past year), Merck.
|
11:30 AM | 083 | Precision Therapy for Neuromyelitis Optica Spectrum Disorder: A Retrospective Analysis of the Use of Class-Switched Memory B-cells for Individualized Rituximab Dosing Schedules |
Disclosure: Dr. Trewin has nothing to disclose.
|
11:30 AM | 084 | New Sensorineural Hearing Loss can be Associated with Disabling Autoimmune Disease |
Disclosure: Dr. Ghavami has nothing to disclose.
|
MS Symptom Assessment and Management | |||
Start Time | Pub. | Title | Presenter |
11:30 AM | 085 | Long-term Effectiveness of 9-d-tetrahydrocannabinol:Cannabidiol Oromucosal Spray in Clinical Practice: results from a 18-months Multicenter Italian Study |
Disclosure: Dr. Patti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Almirall, Bayer, Biogen, Celgene, Merck, Myalin, Novartis, Roche, Sanofi-Genzyme and Teva. Dr. Patti has received research support from MIUR (Ministero Italiano della Università della Ricerca Scientifica), FISM (Fondazione Italiana Sclerosi Multipla), Biogen and Merck.
|
11:30 AM | 086 | Feasibility of Using Wearable Technology with a Social Cognitive Theory-based Physical Activity Promotion Program in Youth with Multiple Sclerosis |
Disclosure: Dr. Grover has nothing to disclose.
|
11:30 AM | 087 | INROADS: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment |
Disclosure: Dr. Cameron has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adamas Corporation and GW Pharmaceuticals. Dr. Cameron has received personal compensation in an editorial capacity for Current Neurology and Neuroscience Reports.
|
11:30 AM | 088 | Which treatments improve fatigue and quality of life in Multiple Sclerosis? Evidence appraisal and development of visual interactive evidence maps |
Disclosure: Dr. Tsou has nothing to disclose.
|
11:30 AM | 089 | Sexual Dysfunction in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Prevalence |
Disclosure: Dr. Kim has nothing to disclose.
|
11:30 AM | 090 | Interoception as a neurocognitive mechanism underlying fatigue in Multiple Sclerosis |
Disclosure: Dr. Gonzalez Campo has nothing to disclose.
|
11:30 AM | 091 | Origins of Fatigue in an Early Multiple Sclerosis Cohort |
Disclosure: Dr. Marino has nothing to disclose.
|
11:30 AM | 092 | A Survey of Cannabis-Based Product Use in Multiple Sclerosis Patients at the University of British Columbia Hospital |
Disclosure: Dr. Schabas has nothing to disclose.
|
11:30 AM | 093 | N-acetyl cysteine for fatigue in progressive multiple sclerosis: A pilot randomized double-blind placebo-controlled trial |
Disclosure: Dr. Krysko has received research support from MS fellowship grant from NMSS; MS fellowship grant from Biogen.
|
11:30 AM | 094 | Telerehabilitation reduces travel cost and time: A survey of participants with multiple sclerosis in an urban treatment setting |
Disclosure: Dr. Best has nothing to disclose.
|
11:30 AM | 096 | The Extent of the Relationship between Sleep Disturbances and walking ability in People with Multiple Sclerosis |
Disclosure: Dr. El-Salem has nothing to disclose.
|
11:30 AM | 097 | A Novel Approach to Treatment of Trigeminal Neuralgia in Multiple Sclerosis Patients Using Minimally Invasive Trigeminal Ablation (MITA) |
Disclosure: Dr. Tajali has nothing to disclose.
|
11:30 AM | 098 | Lacosamide Efficacy in Trigeminal Neuralgia and Other Neuropathic Pain Syndromes: A Case Series |
Disclosure: Dr. Belliston has nothing to disclose.
|
11:30 AM | 099 | Social anxiety among patients with multiple sclerosis: a population-based case-control study in Ecuador |
Disclosure: Dr. Jimenez-Zambrano has nothing to disclose.
|
11:30 AM | 100 | Cannabis Use in People with Multiple Sclerosis and Self-Reported Spasticity |
Disclosure: Dr. Hugos has nothing to disclose.
|
11:30 AM | 101 | Gait and Balance Outcomes in Adrenomyeloneuropathy (AMN) |
Disclosure: Dr. Sadjadi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with HVHPrecision.
|
11:30 AM | 102 | Processing speed of information deficit induces a lack of functional impulsivity in Multiple Sclerosis |
Disclosure: Dr. Joly has nothing to disclose.
|
11:30 AM | 103 | Arabic Modified Fatigue Impact Scale: Validity and Reliability in People with Multiple Sclerosis |
Disclosure: Dr. Alsharman has nothing to disclose.
|
11:30 AM | 104 | Cognitive-motor interaction in Multiple Sclerosis: how it impacts on patient’s Quality of Life. |
Disclosure: Dr. Eizaguirre has nothing to disclose.
|
11:30 AM | 105 | Immunophenotyping of Depression and Fatigue in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated with Dimethyl Fumarate |
Disclosure: Dr. Lee has nothing to disclose.
|
11:30 AM | 106 | Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review Evaluating Symptom Outcomes |
Disclosure: Dr. McCormack has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Mallinkrodt, Biogen and Sanofi Genzyme.
|
11:30 AM | 107 | Evidence of early Central Nervous System degeneration in Multiple Sclerosis patients with impulsivity |
Disclosure: Dr. Capet has nothing to disclose.
|
11:30 AM | 108 | Prevalence and Factors Associated with Anxiety in Argentinian Patients with Multiple Sclerosis |
Disclosure: Dr. Chertcoff has nothing to disclose.
|
11:30 AM | 109 | Demyelinating Disease Associated with Parkinsonism: A Case Report |
Disclosure: Dr. Jordan has nothing to disclose.
|
11:30 AM | 110 | Long-Term Follow-Up and Results of Patients with MRI Negative Demyelinating Diseases |
Disclosure: Dr. Kizek has nothing to disclose.
|
11:30 AM | 111 | The "MS Hug": Definition, Characteristics, Course, and Misattribution Risk |
Disclosure: Dr. Wingerchuk has received personal compensation from MedImmune, Celgene, Novartis Dr. Wingerchuk has received personal compensation in an editorial capacity as co-Editor-in-Chief for The Neurologist. Dr. Wingerchuk has received research support from Alexion and TerumoBCT.
|